OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
DNA Encoded Libraries (DELs) have become an important and efficient approach for identifying novel chemical entities targeting a range of biomolecular architectures.
Barry Morgan led the development of the DEL platform at Praecis Pharmaceuticals, Boston, joining GSK to lead its continued investment in DEL screening after GSK bought Praecis in 2007. Since that time GSK has gone on to publish several novel chemical entities, now in late phase clinical development. What started as a theory from Sydney Brenner & Richard Lerner has truly come of age as a powerful drug-discovery approach.
Barry is now CSO at HitGen, who continue to build a strong DEL platform based in Chengdu, China.
